Treating obesity and type 2 diabetes together can be very challenging. New research revealed today at the European Association for the Study of Diabetes annual meeting showed our investigational triple agonist delivered progress in both. At the highest dose, more than half of participants no longer qualified as having obesity, and nearly 40% reached normal blood sugar levels. See our press release at the link in bio. #EASD2026